What's in Meridian Bioscience, Inc.'s pipeline?

Meridian Bioscience, Inc. has 5 drugs in our index: 4 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Meridian Bioscience, Inc.'s portfolio?

Top competitors by shared drug class: Ahn-Gook Pharmaceuticals Co.,Ltd, AstraZeneca, AstraZeneca (originally Astra AB), Baxter, Charles Mel Wilcox, MD.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/meridian-bioscience-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Meridian Bioscience, Inc. — Portfolio Competitive Intelligence Brief

Meridian Bioscience, Inc. pipeline: 4 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Esomeprazole (Nexium)	Esomeprazole (Nexium)	marketed	Proton pump inhibitor (PPI)	H+/K+-ATPase (proton pump)	Gastroenterology
Omeprezole (Losec)	Omeprezole (Losec)	marketed	Proton pump inhibitor (PPI)	H+/K+-ATPase (proton pump)	Gastroenterology
Lansoprazole (Lanton)	Lansoprazole (Lanton)	marketed	Proton pump inhibitor (PPI)	H+/K+-ATPase (proton pump)	Gastroenterology
Pantoprazole(Controloc)	Pantoprazole(Controloc)	marketed	Proton pump inhibitor (PPI)	H+/K+-ATPase (proton pump)	Gastroenterology
BreathID® Hp Lab System	BreathID® Hp Lab System	phase 3			Gastroenterology / Infectious Disease

Therapeutic area mix

Gastroenterology · 4
Gastroenterology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
AstraZeneca · 1 shared drug class
AstraZeneca (originally Astra AB) · 1 shared drug class
Baxter · 1 shared drug class
Charles Mel Wilcox, MD · 1 shared drug class
China-Japan Friendship Hospital · 1 shared drug class
Chinese University of Hong Kong · 1 shared drug class
Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Meridian Bioscience, Inc.:

Cite this brief

Drug Landscape (2026). Meridian Bioscience, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/meridian-bioscience-inc. Accessed 2026-05-15.